Literature DB >> 25925044

[Role of VEGF in diseases of the retina].

Luis Arias Barquet1.   

Abstract

Angiogenesis is the process through which new blood vessels are formed, based on preexisting vessels, and is the paradigm of diseases such as cancer and exudative ageassociated macular degeneration (ARMD). Several proangiogenic factors have been identified, such as vascular endothelial growth factor (VEGF), especially VEGF-A, which activates endothelial cells and promotes cell proliferation, migration, and an increase in vascular permeability. VEGF is also involved in the etiopathogenesis of other retinal diseases, such as diabetic macular edema and macular edema secondary to retinal vein occlusion. Likewise, there is increasing evidence that placental growth factor (PIGF) acts recepsynergetically with VEGF in promoting these diseases. Currently, the main treatment for these diseases are the anti-VEGF drugs, aflibercept, ranibizumab and bevacizumab. These agents differ in their molecular structure and mechanism of action.
Copyright © 2015 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Angiogénesis; Degeneración macular asociada a la edad exudativa; Diabetic macular edema; Edema macular diabético; Edema macular secundario a oclusiones venosas retinianas; Exudative age-related macular degeneration (ARMD); Factor de crecimiento del endotelio vascular; Factor de crecimiento placentario; Placental Growth Factor (PIGF); Terapia antifactor de crecimiento del endotelio vascular; Vascular Endothelial Growth Factor (VEGF)

Mesh:

Substances:

Year:  2015        PMID: 25925044     DOI: 10.1016/S0365-6691(15)30002-2

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  9 in total

1.  Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies.

Authors:  Gang Qiao; Wan-Jiang Dong; Yan Dai; Zhen-Hua Jiang; Hai-Ke Guo
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

2.  Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients.

Authors:  Amin E Nawar
Journal:  Clin Ophthalmol       Date:  2022-04-19

3.  Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis.

Authors:  Wei Wang; Guang-Xu Liu; Yue-Hua Li; Xue-Dong Li; Yan He
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

4.  Advanced glycation end products accelerate calcification in VSMCs through HIF-1α/PDK4 activation and suppress glucose metabolism.

Authors:  Yi Zhu; Wen-Qi Ma; Xi-Qiong Han; Ying Wang; Xin Wang; Nai-Feng Liu
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

5.  The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion: A protocol for systematic review and meta-analysis.

Authors:  Guang Chen; Peng Chen; Xiaoping Chen; Jing Wang; Xinming Peng
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

Review 6.  Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations.

Authors:  Diego Garcia-Ayuso; Johnny Di Pierdomenico; David García-Bernal; Manuel Vidal-Sanz; María P Villegas-Pérez
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

Review 7.  The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer.

Authors:  Xiaoxia Zhu; Wen Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2015-10-09       Impact factor: 5.555

8.  miR‑140‑5p inhibits the proliferation of multiple myeloma cells by targeting VEGFA.

Authors:  Min Liu; Huimin Liu; Jing Zhou; Zhuojun Yu
Journal:  Mol Med Rep       Date:  2020-11-17       Impact factor: 2.952

9.  Serum progesterone and retinopathy in male patients with type 2 diabetes: A cross-sectional study.

Authors:  Shengnan Sun; Yahao Wang; Yue Zhou; Wenru Ma; Yajing Huang; Jianxia Hu; Yangang Wang
Journal:  J Diabetes Investig       Date:  2020-12-14       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.